Session 8-Oral Abstracts
HIV Prevention: PrEP, Microbicides, and Circumcision
Tuesday, 10 am-12:15 pm; Room 6C
10:00 am         29 ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women
Jared Baeten*1, D Donnell1,2, P Ndase1, N Mugo1, A Mujugira1, C Celum1, and Partners PrEP Study Team
1Univ of Washington, Seattle, US and 2Fred Hutchinson Cancer Res Ctr, Seattle, WA, US
10:15 am         30 Tenofovir Disoproxil Fumarate Drug Levels Indicate PrEP Use Is Strongly Correlated with HIV-1 Protective Effects: Kenya and Uganda
Deborah Donnell*1,2, J Baeten2, C Hendrix3, N Bumpus3, D Bangsberg4, J Haberer4, A Mujugira2, C Celum2, and Partners PrEP Study Team
1Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 2Univ of Washington, Seattle, US; 3Johns Hopkins Univ, Baltimore, MD, US; and 4Massachusetts Gen Hosp, Boston, US
10:30 am    31LB Intracellular Tenofovir-DP Concentrations Associated with PrEP Efficacy in MSM from iPrEx
Peter Anderson*1, A Liu2, S Buchbinder2, J Lama3, J Guanira3, V McMahan4, L Bushman1, D Glidden5, R Grant4,5, and the iPrEx Study Team
1Univ of Colorado Denver, Aurora, US; 2San Francisco Dept of Publ Hlth, CA, US; 3Investigaciones Med en Salud, Lima, Peru; 4Gladstone Inst of Virology and Immunology, San Francisco, CA, US; and 5Univ of California, San Francisco, US
10:45 am    32LB The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women
Lut Van Damme*1, A Corneli1, K Ahmed2, K Agot3, J Lombaard4, S Kapiga5,6, R Grant7, A Kashuba8, T Crucitti9, D Taylor1, and FEM-PrEP Study Group
1FHI 360, Durham, NC, US; 2Setshaba Res Ctr, Pretoria, South Africa; 3Impact Res and Devt Org, Kisumu, Kenya; 4JOSHA Res, Bloemfontein, South Africa; 5London Sch of Hygiene and Tropical Med, UK; 6Kilimanjaro Christian Med Ctr, Moshi, Tanzania; 7Gladstone Inst of Virology and Immunology, San Francisco, CA, US; 8Univ of North Carolina at Chapel Hill, Eshelman Sch of Pharmacy, US; and 9Inst of Tropical Med, Antwerp, Belgium
11:00 am         33 Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital Tract of Women with Breakthrough Infections: CAPRISA 004 Tenofovir Gel Trial
X Wei1, L Morris2, V Naranbhai3, S Sibeko3, Q Abdool Karim3,4, A Kashuba5, J-A Passmore3,6, G Hunt2, W Heneine1, and Jeffrey Johnson*1
1CDC, Atlanta, GA, US; 2Natl Inst for Communicable Diseases, Johannesburg, South Africa; 3Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu-Natal, Durban; 4Columbia Univ, New York, NY, US; 5Univ of North Carolina at Chapel Hill, US; and 6Natl Hlth Lab Svc, Johannesburg, South Africa
11:15 am    34LB MTN-007: A Phase 1 Randomized, Double-blind, Placebo-controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel
Ian McGowan*1, C Hoesley2, P Andrew3, L Janocko4, J Dai5,6, A Carballo-Dieguez7, R Kunjara Na Ayudhya4, J Piper8, R Cranston1, K Mayer9, and MTN-007 Protocol Team
1Univ of Pittsburgh Sch of Med, PA, US; 2Univ of Alabama at Birmingham, US; 3FHI 360, Durham, NC, US; 4Magee-Women`s Res Inst, Pittsburgh, PA, US; 5Univ of Washington, Seattle, US; 6Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 7Columbia Univ, New York, NY, US; 8DAIDS, NIAID, NIH, Bethesda, MD, US; and 9Fenway Hlth, Boston, MA, US
11:30 am         35 Rilpavirine-LA Formulation: Pharmacokinetics in Plasma, Genital Tract in HIV– Females and Rectum in Males
Akil Jackson*1, L Else2, J Tjia2, N Seymour1, M Stafford1, D Back2, B Gazzard1, and M Boffito1
1St Stephen`s AIDS Trust, London, UK and 2Univ of Liverpool, UK
11:45 am         36 Population-level Impact of Male Circumcision on HIV Incidence: Rakai, Uganda
Ronald Gray*1,2, G Kigozi2, D Serwadda2,3, X Kong1, F Nalugoda2, F Makumbi2,3, J Kagaayi2, T Lutalo2, S Watya4, and M Wawer1,2
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2Rakai Hlth Sci Prgm, Entebbe, Uganda; 3Makerere Univ Sch of Publ Hlth, Kampala, Uganda; and 4Makerere Univ, Mulago Hosp, Kampala, Uganda
12:00 pm         37 ANRS-12126—Impact of Male Circumcision Roll-out on HSV-2 Prevalence among Men: Orange Farm, South Africa
Bertran Auvert*1,2,3, A Blake3, V Maseko4, P Lissouba2, D Lewis4, and D Taljaard5
1Univ of Versailles, France; 2UMR S1018, Villejuif, France; 3Assistance Publ Hosp de Paris, France; 4Natl Inst for Communicable Diseases, Natl Hlth Lab Svc, Sandringham, South Africa; and 5Progressus, Johannesburg, South Africa